4892.T) announced">
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 10, 2026. It represents a primary source document for Japanese Compensation sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 10, 2026 Cyfuse Biomedical K.K. [4892.T] TOKYO, Feb 10 (Pulse News Wire) – Cyfuse Biomedical K.K. (4892.T) announced today that the issuance details of its 25th round of stock options (stock options) to employees have been finalized based on the resolution made at the board meeting held on January 22, 2026. In the latest issuance, a total of 200 stock options will be granted to 12 company employees. The stock options are tied to ordinary shares totaling 2